Elephas Names Dr. Pascual Starink Vice President, Software Engineering & Analytics
Madison, WI, April 1, 2021 -- Elephas Biosciences Corporation (Elephas), a live tumor imaging company developing novel cancer diagnostic solutions, announced today the appointment of Dr. Pascual Starink as Vice President, Software Engineering & Analytics.
Dr. Starink is an established leader with significant research experience at the intersection of technology and life sciences across the biotech, pharmaceutical, and consulting industries. Dr. Starink will be leading the software and analytics efforts of the company, leveraging his experience to develop the cloud-enabled infrastructure that underlies the Elephas platform.
"We are pleased to announce another significant addition to the leadership team," said Maneesh Arora, founder and CEO of Elephas. "Pascual’s experience and background will be a key asset as we continue to build our oncology platform.”
Dr. Starink began his post-doctoral career as the Director of Software and Process Engineering at Perlegen Sciences, where he worked for six years and lead development of a custom LIMS system. After Perlegen, Dr. Starink joined Genomic Health as the IT Director for R&D before serving as Sr. Director, IT for R&D at Celgene for six years.
"Advances in cancer biology, microscopy, and AI have presented the opportunity to combine these techniques into a singular platform and improve outcomes for cancer patients everywhere. That is what we are aiming to do at Elephas, and why I am so excited to join” said Dr. Starink.
Dr. Starink earned his bachelor’s degree in computer science and his PhD in applied physics at the Delft University of Technology. He also completed a postdoctoral fellowship at the Max Planck Institute for Biophysical Chemistry.
Disruption in healthcare is being accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision making and accelerate drug development. We plan to use the power of our platform to deliver a global solution that can revolutionize cancer treatment for every individual. To learn more, visit us at www.elephas.com or follow us on LinkedIn.
CGLife on Behalf of Elephas